Meanwhile, the BSE Sensex was up 131.47 points or 0.79% to 16,850.34.
On BSE, 2.15 lakh shares were traded in the counter as against average daily volume of 1.02 lakh shares in the past one quarter.
The stock hit a high of Rs 587.30 and a low of Rs 578.25 so far during the day. The stock had hit a record high of Rs 610 on 2 May 2012. The stock had hit a 52-week low of Rs 448.20 on 4 October 2011.
The stock had underperformed the market over the past one month till 8 June 2012, falling 2% compared with the Sensex`s 1.04% rise. The stock had, however, outperformed the market in past one quarter, rising 4.64% as against Sensex`s 2.49% decline.
The large-cap pharmaceutical company has an equity capital of Rs 103.56 crore. Face value per share is Re 1.
The Sun Pharmaceutical Industries stock had risen 4.5% in three trading sessions to settle at Rs 583.80 on Friday, 8 June 2012, from a recent low of Rs 558.65 on 5 June 2012.
Sun Pharmaceutical Industries` consolidated net profit jumped 85.3% to Rs 820.21 crore on 59.2% growth in net sales to Rs 2329.93 crore in Q4 March 2012 over Q4 March 2011.
Sun Pharmaceutical Industries is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.
Powered by Capital Market - Live News